Skip to main content
Premium Trial:

Request an Annual Quote

Bruker, Chungnam National University Partner on Glycan Analysis

NEW YORK (GenomeWeb News) – Bruker and Chungnam National University in South Korea announced today a collaboration to develop MALDI-TOF-based methodologies for the analysis of glycans.

The deal between Bruker and the Graduate School of Analytical Science and Technology at the university will be targeted mainly at creating methods and software applications in the development and quality control of biologics, such as therapeutic antibodies, they said.

The partnership will also serve as an Asia Glycomics Reference Site and provide support to the wider Asian Glycomics community, they added. The work is expected to "create a better understanding of the function of glycans in biomolecules and their key role in many biological processes."

Financial and other terms of the deal were not disclosed.

The research will be led by Hyun Joo An, a professor at the university, and Detlev Suckau at Bruker.

"The potential we see, particularly for the biosimilar industry, indicates that glycan research will continue to increase in importance, particularly as workflows develop to unravel its complexities," An said in a statement.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.